Truist Financial Corp Increases Stock Position in Humana Inc. (NYSE:HUM)

Truist Financial Corp grew its stake in shares of Humana Inc. (NYSE:HUM) by 15.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,865 shares of the insurance provider’s stock after buying an additional 1,199 shares during the period. Truist Financial Corp’s holdings in Humana were worth $2,249,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in HUM. Pinnacle Wealth Management Advisory Group LLC boosted its position in Humana by 3.6% during the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock worth $272,000 after purchasing an additional 37 shares during the period. Atlas Brown Inc. boosted its position in Humana by 0.6% during the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock worth $1,611,000 after purchasing an additional 38 shares during the period. Moors & Cabot Inc. boosted its position in Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares during the period. Mather Group LLC. boosted its position in Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock worth $60,000 after purchasing an additional 41 shares during the period. Finally, Your Advocates Ltd. LLP boosted its position in Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

NYSE HUM opened at $255.06 on Thursday. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market cap of $30.77 billion, a price-to-earnings ratio of 25.63, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56. The company has a 50-day moving average price of $270.12 and a two-hundred day moving average price of $288.06.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.39%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is 35.58%.

Analysts Set New Price Targets

HUM has been the topic of a number of recent analyst reports. Barclays boosted their price objective on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. StockNews.com upgraded shares of Humana from a “hold” rating to a “buy” rating in a report on Tuesday. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Finally, Piper Sandler upped their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Nineteen equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $285.68.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.